Innocoll Holdings
Manufacturing · Ireland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Block D Monksland Business Park unit 9, ...Phone Number
(484) 406-5200Website
www.innocoll.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Innocoll Holdings
Innocoll, founded in 1985 and based in Athlone, ireland, is a global, specialty pharmaceutical company with late stage development programs that is dedicated to engineering better medicines to help patients get better. Their proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use.Explore more
Innocoll Holdings Org Chart
RK
Sales Director, Northeast Region
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Innocoll Holdings your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Innocoll Holdings is spiking on competitors!
Earning: See what the market has to say on Innocoll Holdings recently announced quarterly report
Check if Innocoll Holdings has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Innocoll Holdings
Innocoll Holdings, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Innocoll Holdings has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Innocoll Holdings launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Innocoll Holdings had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Innocoll Holdings
Find 2 more new buyers
Company Profile Activity
Activity Insights
Innocoll Holdings is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Innocoll Holdings is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Innocoll Holdings.
Innocoll Holdings financials insights
Gather financial insights about Innocoll Holdings, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Private Equity
$30M
2014
Stock Offering
$58.5M
2022
Debt
$125M
Innocoll Holdings Tech Stack
A closer look at the technologies used by Innocoll Holdings
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Funding
Executive Move
Michele Bouniol has been appointed as Director, HR Operations and HRIS.
Executive Moves
Promotion
Executive Move
Innocoll Holdings News & Media
Innocoll and DURECT Announce U.S. launch of POSIMIR®
POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone...Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression
ATHLONE, Ireland--(BUSINESS WIRE)--Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced today the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® (bupivacaine solution) for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After ArthroscInnocoll Announces Positive Topline Results For XARACOLL® (bupivacaine hydrochloride) implant in a Phase 3 Study to Support Expanded Use
ATHLONE, Ireland--(BUSINESS WIRE)--Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced today positive topline results from Study INN-CB-024, a Phase 3 randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a 300mg dose of XARACOLL, an innovative collagen drug-device implant, in patients undergoing abdominoplasty. Among patients receiving XARACOLL, a reduction in pain intensity andInnocoll Announces Successful Completion of Debt Refinancing
ATHLONE, Ireland--(BUSINESS WIRE)--Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today the successful refinancing of its existing term loan facility with a new $125 million term loan provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The new term loan meaningfully strengthens Innocoll’s financial flexibility and enables the Company to further invest in its R&D program and commercial organiza
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Innocoll Holdings
Sign Up For FreeTo access detailed company insights
Innocoll, founded in 1985 and based in Athlone, ireland, is a global, specialty pharmaceutical company with late stage development programs that is dedicated to engineering better medicines to help patients get better. Their proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use.... Read More
